Skip to main content
Cureus logoLink to Cureus
. 2022 Oct 14;14(10):c78. doi: 10.7759/cureus.c78

Correction: Phase 1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases

Jesus A Perez 1,, Javier J Lopez 2, Claudia C Torres Badillo 3, Jaya Gill 4, Santosh Kesari 4, Peter Novak 5, Max Temnikov 5, Roman Byshovets 6, Oleg Bychkov 6
Editors: Alexander Muacevic, John R Adler
PMCID: PMC9647232  PMID: 36397903

Authors Jaya Gill and Santosh Kesari have been added to the published article after they were mistakenly omitted from the original submission by the submitting author. The authors deeply regret this error.

 

The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

Footnotes

No competing interests declared.


Articles from Cureus are provided here courtesy of Cureus Inc.

RESOURCES